
Sign up to save your podcasts
Or


Dr. Jung-Mo Ahn, Associate Professor of Chemistry, University of Texas at Dallas
September 14, 2022
In this episode, we discuss the use of small molecules as targeted treatments to interrupt the regulatory pathways responsible for cancer growth, neurodegenerative diseases, and other conditions, with relatively minimal off-target effects.
By Johns Hopkins Center for Health SecurityDr. Jung-Mo Ahn, Associate Professor of Chemistry, University of Texas at Dallas
September 14, 2022
In this episode, we discuss the use of small molecules as targeted treatments to interrupt the regulatory pathways responsible for cancer growth, neurodegenerative diseases, and other conditions, with relatively minimal off-target effects.